AzTrials
AzTrials

Non-Malignant Hematologic DisordersPhase 2NCT03615144

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

A Phase 2 study testing Melphalan, Thiotepa and Clofarabine in people with Non-Malignant Hematologic Disorders, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease. Read more about this study

Who is it for?
Ages 1 year to 69 years
Conditions the study is for
Non-Malignant Hematologic Disorders
What is being tested?
Melphalan, Thiotepa and Clofarabine
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1 participants
Where
1 siteUnited States
Study dates
23 Jul 2018to 13 Nov 2020
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 69 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Subject Inclusion Criteria:

  • Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is indicated including:
  • Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least one of the following criteria (Walters et al):
  1. Cerebrovascular accident lasting longer than 24 hours
  2. Impaired neuropsychological function with abnormal brain MRI/MRA
  3. Recurrent hospitalizations (>2 episodes/year over several years) or exchange transfusions for acute chest syndrome
  4. Recurrent priapism
  5. Stage I or II sickle chronic lung disease
  6. Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration rate 30-50% of predicted normal value for age)
  7. Bilateral proliferative retinopathy with major visual impairment in at least one eye
  8. Osteonecrosis of multiple joints
  9. Red cell alloimmunization during chronic transfusion therapy
  • Thalassemia major with at least one of the following criteria:
  1. Age <16 years
  2. Available HLA-identical sibling
  3. Red blood cell transfusion dependency
  4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy)
  5. Recurrence of disease after previous stem cell transplant
  • Bone Marrow Failure Syndromes:
  1. Aplastic anemia refractory to immunosuppressive therapy
  2. Diamond Blackfan Anemia refractory to conventional therapy
  3. Shwachman-Diamond Syndrome
  4. Severe Congenital Neutropenia
  5. Congenital Amegakaryocytic Thrombocytopenia
  6. Thrombocytopenia Absent Radii syndrome
  7. Other marrow failure disorders not otherwise specified
  • Autoimmune cytopenias refractory to all conventional treatments
  1. Autoimmune hemolytic anemia
  2. Immune thrombocytopenia
  3. Evan's syndrome
  4. Pure red cell aplasia
  • Histiocytic disorders:
  1. Hemophagocytic lymphohistiocytosis
  2. High risk, recurrent or refractory Langerhans cell histiocytosis
  3. Secondary HLH

Subject Inclusion Criteria:

  • Recipient's age birth to < 70 years old
  • Patients must have adequate organ function measured by:
  • Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must improve with exercise.
  • Hepatic: < 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant for. Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with PI approval e.g. patients with PNH, Gilbert"s disease or other hemolytic disorders.
  • Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for hemoglobin).
  • Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 70 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
  • Normal GFR in Children and Young Adults.

Donor Inclusion Criteria:

  • Each donor must meet criteria outlined by institutional guidelines and be medically eligible to donate according to NMDP (or equivalent donor search organization) criteria including testing for antibodies to Human TLymphotrophic Virus Types I \& II (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and Zika.
  • Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.
  • Donor should be healthy and agree to receive G-CSF followed by donation of peripheral blood stem cells.
  • Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC collection).
  • Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A, B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.

Subject Exclusion Criteria:

  • Female patients who are pregnant or breast-feeding
  • Active viral, bacterial or fungal infection
  • Patient seropositive for HIV-I/II; HTLV-I/II
  • Karnofsky (adult)/Lansky (pediatric) < 70%
  • Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are presently undergoing transplantation based on a multi-center protocol
  • Patients with Thalassemia major with Pesaro risk score >II
  • Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII), α-Mannosidosis, X- ALD, Osteopetrosis

Donor Exclusion Criteria:

  • Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are pregnant or breastfeeding will not be eligible for this study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Memorial SloanKettering Cancer Center

    New York, New York, 10065

Other trials in United States

About this study

Official title: A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.

Being tested
Melphalan, Thiotepa, Clofarabine, Fludarabine, Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Keywords
T-cell, B-cell, CliniMACS System, Melphalan, Thiotepa, Clofarabine, Fludarabine, 17-596

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MelphalanDrug

    Melphalan 70 mg/m2/day x 2

  • ThiotepaDrug

    Thiotepa 7.5 mg/kg/day x 2

  • ClofarabineDrug

    Clofarabine 20-30 mg/m2/day x 5

  • FludarabineDrug

    Fludarabine 30 mg/m2/day x 5

  • Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)Drug

    antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.

  • CliniMACS reagentsProcedure or surgery

    Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.

Study groups in NCT03615144
Study groupRoleWhat they receive
Melphalan/Thiotepa/ClofarabineActive comparatorMelphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Receives: Drug: Melphalan; Drug: Thiotepa; Drug: Clofarabine; Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®); Procedure: CliniMACS reagents
Melphalan/Thiotepa/ FludarabineActive comparatorMelphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Receives: Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®); Procedure: CliniMACS reagents

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Survival (OS)

    Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2018
  2. Study start23 Jul 2018
  3. Primary completion13 Nov 2020
  4. Study completion13 Nov 2020

Why it stopped: Participant accrual low and the study was closed

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.
Masking
None (open label)
Enrolment
1 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03615144
Sponsor's protocol ID
17-596
Status last verified
Nov 2020
First submitted
30 Jul 2018
Last updated
24 Mar 2021
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Melphalan, Thiotepa and Clofarabine in people with Non-Malignant Hematologic Disorders, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 24 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Survival (OS) (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in